Litigation Details for Pfizer Inc. v. C.P. Sun Pharmaceutical Industries Limited (D. Del. 2017)

Pfizer Inc. v. C.P. Sun Pharmaceutical Industries Limited (D. Del. 2017)

Docket		Date Filed	2017-02-14
Court	District Court, D. Delaware	Date Terminated	2019-03-07
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	C.P. PHARMACEUTICALS INTERNATIONAL C.V.
Patents	6,965,027
Attorneys	Karen Elizabeth Keller
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Pfizer Inc. v. C.P. Sun Pharmaceutical Industries Limited (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-02-14				External link to document
2017-02-13	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,965,027 B2. (ceg) (Entered:…2017 7 March 2019 1:17-cv-00159 830 Patent None District Court, D. Delaware	External link to document

Pfizer Inc. v. C.P. Pharmaceuticals International C.V. and Sun Pharmaceutical Industries Limited: Litigation Summary and Patent Analysis

Last updated: August 12, 2026

Pfizer’s 2017 Delaware action against C.P. Pharmaceuticals International C.V. and Sun Pharmaceutical Industries Limited challenged Sun’s ANDA for generic sildenafil citrate tablets, the active pharmaceutical ingredient in Viagra. The case centered on Pfizer’s U.S. Patent No. 6,469,012, an Orange Book-listed patent covering sildenafil for treating erectile dysfunction. The action was resolved through a settlement and subsequent dismissal, allowing Sun to enter before the patent’s nominal expiration under agreed conditions. [1][2]

What drug and patent were involved in Pfizer v. Sun Pharmaceutical?

The case involved sildenafil citrate tablets, marketed by Pfizer as Viagra.

Item	Detail
Brand drug	Viagra
Active ingredient	Sildenafil citrate
Dosage form	Oral tablets
Therapeutic category	Phosphodiesterase-5 inhibitor
Reference sponsor	Pfizer Inc.
ANDA applicant	C.P. Pharmaceuticals International C.V., affiliated with Sun Pharmaceutical Industries
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-00159
Filing date	February 3, 2017
Principal patent	U.S. Patent No. 6,469,012
Regulatory pathway	Abbreviated New Drug Application
Litigation posture	Paragraph IV patent litigation
Disposition	Settlement followed by dismissal

Pfizer alleged that Sun’s ANDA product would infringe claims of U.S. Patent No. 6,469,012. The patent covered the use of sildenafil and related compounds for treating erectile dysfunction. Pfizer listed the patent in the FDA Orange Book for Viagra. [2][3]

What patents protected Viagra against Sun’s generic ANDA?

The principal asserted patent was U.S. Patent No. 6,469,012, titled "Pyrazolopyrimidinones for the treatment of impotence." The patent issued in 2002 and was assigned to Pfizer-related entities.

U.S. Patent No. 6,469,012

Field	Detail
Patent number	6,469,012
Patent family	Sildenafil and related pyrazolopyrimidinone compounds
Patent holder	Pfizer-related entities
Use covered	Treatment of erectile dysfunction
Orange Book status	Listed for Viagra
Stated expiration	March 27, 2020
Litigation role	Core patent asserted against Sun’s ANDA

The patent’s claims were method-of-use claims rather than a simple composition claim directed only to sildenafil as a chemical compound. That distinction mattered because generic applicants could seek approval for uses outside the patented indication or use labeling strategies designed to omit patented indications. Pfizer nevertheless treated Sun’s ANDA filing as an act of infringement under 35 U.S.C. § 271(e)(2). [1][3]

What was Sun’s Paragraph IV challenge?

Sun’s ANDA included a Paragraph IV certification asserting that Pfizer’s listed patent was invalid, unenforceable, or would not be infringed by Sun’s proposed generic sildenafil product.

A Paragraph IV certification creates an artificial act of patent infringement under the Hatch-Waxman Act. Pfizer’s complaint triggered the statutory 30-month stay of FDA approval, subject to earlier resolution by settlement, judgment, or other termination of the litigation. [1][4]

The case therefore did not involve an allegation that Sun had already marketed infringing sildenafil. It concerned Sun’s proposed commercial manufacture and sale after FDA approval.

When did Pfizer file the lawsuit against Sun?

Pfizer filed the action on February 3, 2017, in the District of Delaware. The complaint followed Sun’s ANDA filing and Paragraph IV notice concerning generic sildenafil citrate tablets. [1]

The filing occurred during an active period of generic competition for Viagra. Teva Pharmaceuticals had already reached an agreement with Pfizer that permitted an earlier generic launch, and other ANDA applicants sought similar market access. The commercial value of the case depended less on whether generic entry would occur and more on its timing, launch conditions, and any restrictions contained in a settlement.

How did Pfizer v. Sun end?

The litigation ended through a settlement followed by dismissal. The public docket does not disclose the complete commercial terms of the agreement, including any payment terms, supply arrangements, or restrictions applicable to Sun. [1]

The resolution was consistent with Pfizer’s broader strategy in Viagra litigation: preserve enforceability of the listed patent while controlling the timing and structure of generic entry. The settlement avoided the risk of an adverse judgment on validity or infringement and eliminated the cost of a full trial.

Sun obtained a path to market before the patent’s stated March 2020 expiration. The settlement therefore had greater commercial significance than a simple post-expiration dismissal.

Did Sun receive a generic launch date before Viagra patent expiration?

Yes. The settlement permitted Sun to market generic sildenafil before the nominal expiration of U.S. Patent No. 6,469,012, subject to the agreement’s terms.

The publicly reported generic-entry framework for Viagra allowed certain generic applicants to enter before March 2020. Teva began selling an authorized generic version in December 2017 under its agreement with Pfizer. Other applicants, including Sun, obtained market access through settlements or subsequent regulatory approvals. [5][6]

The Sun litigation was therefore an entry-timing dispute rather than a case expected to maintain indefinite exclusivity through the full patent term.

What was the Orange Book status of Viagra?

The FDA Orange Book listed U.S. Patent No. 6,469,012 for Viagra. The listing required ANDA applicants to address the patent through one of the statutory certification pathways.

Orange Book issue	Analysis
Listed patent	U.S. Patent No. 6,469,012
Certification likely at issue	Paragraph IV
30-month stay	Triggered by Pfizer’s infringement action
Product affected	Sildenafil citrate tablets
Regulatory authority	FDA ANDA review
Post-settlement position	Generic approval and commercial entry subject to agreement terms

The Orange Book listing gave Pfizer a statutory mechanism to challenge Sun before approval. It did not guarantee that Pfizer would retain market exclusivity until 2020. A settlement could authorize earlier entry, and a court decision could have invalidated or narrowed the patent.

How strong was Pfizer’s patent estate against generic sildenafil?

Pfizer’s patent position was commercially strong but structurally concentrated.

Strengths

The core advantages were:

1. U.S. Patent No. 6,469,012 was listed in the Orange Book.
2. The patent had an extended commercial life well beyond Viagra’s initial launch period.
3. The patent covered the approved erectile-dysfunction indication.
4. Pfizer could invoke the 30-month stay after receiving a Paragraph IV notice.
5. The product had substantial brand recognition and established prescribing demand.

Weaknesses

The principal weaknesses were:

1. The patent estate was relatively narrow compared with products protected by multiple compound, formulation, polymorph, dosage, and manufacturing patents.
2. Generic applicants could challenge validity and claim scope through Paragraph IV certifications.
3. Method-of-use claims can create design-around opportunities through labeling restrictions.
4. Sildenafil had become commercially familiar, increasing the incentive for multiple generic entrants.
5. Settlement pressure increased as multiple ANDA applicants approached approval.

Pfizer’s position was strongest as a delay and negotiation tool. It was less secure as a basis for preventing all generic competition through the full patent term.

Were formulation patents or manufacturing patents central to the case?

No. The public record identifies the litigation as a patent dispute involving Pfizer’s Viagra-related method-of-use patent, not as a case focused principally on a separate extended-release formulation, tablet coating, polymorph, or manufacturing process.

The asserted rights did not create the type of layered formulation barrier seen in products protected by multiple later-generation patents. Sun’s product was a conventional oral sildenafil tablet, which limited the practical value of formulation-based exclusion.

Manufacturing patents can still affect generic entry if they are valid, listed, and infringed. In this case, the publicly identified dispute centered on the Orange Book-listed Viagra patent and the ANDA certification rather than a manufacturing-process blockade. [1][2]

Did biosimilar risk apply to Pfizer v. Sun?

No. Biosimilar law was not relevant.

Sildenafil is a small-molecule drug, and Sun’s product proceeded through the ANDA pathway under the Hatch-Waxman Act. The case did not involve a biologic license application, a biologics patent dance, or a biosimilar application under the Public Health Service Act.

The appropriate competitive-risk categories were:

• Paragraph IV invalidity or noninfringement litigation
• Authorized-generic competition
• At-risk generic launch
• Settlement-controlled entry
• Post-expiration price erosion

Which companies challenged Viagra’s patent estate?

Pfizer faced multiple generic applicants and commercial competitors for sildenafil. Teva was the most prominent early entrant because Pfizer agreed to permit Teva to market an authorized generic before the patent’s nominal expiration. Sun was one of the companies that pursued its own ANDA and resolved its Paragraph IV dispute through settlement. [5]

The competitive landscape included:

Company	Role
Pfizer	Viagra sponsor and patent owner
Teva	Early authorized-generic entrant
Sun Pharmaceutical	ANDA applicant and litigation defendant
Other ANDA applicants	Potential later generic entrants
FDA	ANDA approval authority

The presence of several applicants reduced Pfizer’s ability to preserve a single-generic market. It also increased the probability that settlements would establish staggered entry dates rather than eliminate generic competition.

What litigation risk did Sun face?

Sun faced ordinary Hatch-Waxman litigation risk:

• A finding that its ANDA product infringed the asserted patent
• Continued delay in FDA approval during the statutory stay
• Potential damages if it launched before patent expiry and lost
• An injunction restricting commercial launch
• Litigation costs and settlement obligations

Sun’s principal benefit from settlement was certainty. It avoided the risk of an adverse validity or infringement judgment while obtaining an agreed route to commercial entry. Pfizer gained control over timing without having to prove the patent’s validity and infringement at trial.

What was the commercial impact of the settlement?

The settlement reduced Pfizer’s risk of immediate invalidation while accelerating the predictable transition from branded Viagra to generic sildenafil.

For Pfizer, the commercial consequences included:

• Continued Viagra sales during the pre-entry period
• Reduced probability of an at-risk launch
• Preservation of settlement leverage against other ANDA applicants
• Earlier erosion once multiple generics entered
• Potential reduction in litigation expenses

For Sun, the agreement provided:

• A defined launch pathway
• Avoidance of trial risk
• Access to a large and established erectile-dysfunction market
• An opportunity to compete after regulatory approval
• Reduced uncertainty over the patent’s enforceability

Generic sildenafil entry created substantial price pressure because the product had no complex delivery system and did not require specialized manufacturing infrastructure. The principal barriers were FDA approval, supply scale, market access, and the patent settlement, rather than difficult formulation technology.

What is the current legal and regulatory significance of the case?

The case is closed and does not present an ongoing injunction or active trial risk against Sun under the identified docket. Its continuing significance is commercial and strategic.

The case illustrates how an Orange Book-listed method-of-use patent can support a settlement that permits pre-expiration generic entry. It also shows the limits of a single-patent strategy where multiple ANDA applicants are approaching the market and the product has a relatively straightforward oral dosage form.

The case should not be interpreted as a judicial determination that U.S. Patent No. 6,469,012 was valid, enforceable, and infringed. Because the dispute ended by settlement, the court did not issue a merits judgment resolving those questions.

Key Takeaways

• Pfizer sued Sun in Delaware over an ANDA for generic sildenafil citrate tablets.
• The principal patent was U.S. Patent No. 6,469,012, listed in the Orange Book for Viagra.
• Sun’s Paragraph IV certification triggered Pfizer’s Hatch-Waxman infringement action.
• The case ended through settlement and dismissal rather than a trial judgment.
• Sun obtained a pathway to pre-expiration entry under confidential settlement terms.
• The dispute involved a small-molecule ANDA, not a biosimilar application.
• Pfizer’s patent position was commercially effective but concentrated around a principal method-of-use patent.
• The product’s simple oral formulation created substantial long-term generic price-erosion risk.

FAQs

Did Pfizer win or lose Pfizer v. Sun Pharmaceutical?

Neither party obtained a merits judgment. The case was resolved by settlement and dismissed, so the court did not rule that the patent was valid, infringed, or enforceable.

Was Sun’s generic Viagra approved by the FDA?

Sun pursued FDA approval through an ANDA for generic sildenafil. The litigation settlement addressed the patent barrier, while FDA approval remained a separate regulatory requirement.

Did the case involve Viagra’s active ingredient or only its use?

The dispute principally concerned Pfizer’s patent claims covering sildenafil-related treatment of erectile dysfunction. The litigation was not limited to a manufacturing-process dispute.

Could Sun launch generic sildenafil before March 2020?

Yes. The settlement provided a mechanism for entry before the stated expiration of U.S. Patent No. 6,469,012, subject to the confidential terms of the agreement and FDA approval.

Did Pfizer receive damages from Sun?

The public disposition does not establish a damages award. Because the case ended through settlement, any financial terms were not disclosed in the public docket.

References

1. U.S. District Court for the District of Delaware. (2017). Pfizer Inc. v. C.P. Pharmaceuticals International C.V. et al., No. 1:17-cv-00159, docket filings and dismissal record.

2. U.S. Food and Drug Administration. (2020). Approved drug products with therapeutic equivalence evaluations: Viagra (sildenafil citrate) tablets. FDA Orange Book.

3. U.S. Patent and Trademark Office. (2002). U.S. Patent No. 6,469,012: Pyrazolopyrimidinones for the treatment of impotence.

4. Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).

5. Pfizer Inc. (2017). Pfizer announces agreement with Teva regarding generic Viagra. Company release.

6. U.S. Food and Drug Administration. (2017). FDA approves first generic Viagra. FDA press announcement.